Ana Irigaray
About Ana Irigaray
Ana Irigaray is the Senior Director of Regulatory Affairs at BeiGene in Basel, Switzerland, with over 25 years of experience in the biotechnology industry, particularly in oncology.
Senior Director Regulatory Affairs at BeiGene
Ana Irigaray currently holds the position of Senior Director Regulatory Affairs at BeiGene in Basel, Switzerland. In this role, she is responsible for overseeing regulatory strategies and ensuring compliance with regulations in the biotechnology sector. Her expertise is utilized to navigate complex regulatory environments and support the company's objectives, particularly in oncology.
Previous Role at Recordati Rare Diseases Endocrinology
From 2019 to 2021, Ana Irigaray served as the Global Head of Regulatory Affairs at Recordati Rare Diseases Endocrinology. During her two-year tenure in Basel, Switzerland, she led global regulatory strategies and played a key role in securing approvals and compliance for rare disease therapies.
Career at PharmaMar S.A.
Ana Irigaray spent a significant portion of her career at PharmaMar S.A. She initially served as the Regulatory Affairs Group Head from 2002 to 2014 in Colmenar Viejo, Madrid, before being promoted to Regulatory Affairs Director from 2014 to 2019. During these 17 years, she managed regulatory operations and ensured the company’s pioneering cancer treatments adhered to stringent regulations.
Early Career and Roles in Regulatory Affairs
Ana Irigaray's early career includes roles such as Jefe de Registros at GlaxoSmithKline’s production plant in Aranda de Duero, Spain (2000-2002), and Corporate Regulatory Affairs Manager at Laboratoires Galderma S.A. in Paris, France (1995-2000). These roles helped establish her foundation in regulatory affairs, focusing on compliance and regulatory submissions.
Educational Background
Ana Irigaray studied at the University of Navarra, where she earned a Pharmacy degree and a Pharm D from 1985 to 1990. This educational foundation provided her with the knowledge required for a career in regulatory affairs, particularly within the biotechnology and pharmaceutical industries.